LAB missed EPS expectations by 39.70%
Jul 31, 2024, 9:32 PM
0.00%
What does LAB do
Standard BioTools Inc., based in South San Francisco, California, offers biotechnology tools and services for clinical research, focusing on proteomics and genomics through technologies like mass cytometry and microfluidics. The company, which employs 523 people and went public in 2011, collaborates globally with various research sectors including oncology and immunology.
Standard BioTools (LAB) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Standard BioTools's actual EPS was -$0.12, missing the estimate of -$0.09 per share, resulting in a -39.70% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.